title: Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism.
abstract: Treatment with a vitamin D receptor activator (VDRA) has survival benefits probably related to its effects beyond the traditional role in mineral metabolism. We hypothesized that VDRA reduces oxidative stress in hemodialysis (HD) patients. To test this hypothesis, we investigated the effect of VDRA on the oxidative status of albumin in HD patients with secondary hyperparathyroidism. Eleven HD patients with secondary hyperparathyroidism were treated with calcitriol at an intravenous dose of 1.5 µg/week for four weeks. Serum intact parathyroid hormone, calcium and phosphorus were monitored and we measured the amount of oxidized albumin and albumin hydroperoxides form before and after calcitriol treatment. The ratio of oxidized to un-oxidized albumin was determined as a representative marker of oxidative stress. The radical scavenging activity of albumin was also evaluated. After four weeks of calcitriol therapy, there were no significant changes in serum intact parathyroid hormone, calcium, or phosphorus levels; however, the ratio of oxidized to un-oxidized albumin was markedly decreased and serum thiol content was significantly increased after calcitriol treatment. Furthermore, the radical scavenging activity of albumin was greater after calcitriol treatment compared with that of untreated albumin. Our data suggest that intravenous calcitriol treatment reduces oxidative stress and strengthens antioxidant defenses by inhibiting albumin oxidation in HD patients with secondary hyperparathyroidism.
authors.affiliation: Department of Nephrology, Akebono Clinic, Kumamoto, Japan. tanaka@matusita-kai.or.jp
authors.forename: Motoko
authors.initials: M
authors.lastname: Tanaka
authors.forename: Koki
authors.initials: K
authors.lastname: Tokunaga
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Komaba
authors.forename: Kazuko
authors.initials: K
authors.lastname: Itoh
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Matsushita
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Watanabe
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kadowaki
authors.forename: Toru
authors.initials: T
authors.lastname: Maruyama
authors.forename: Masaki
authors.initials: M
authors.lastname: Otagiri
authors.forename: Masafumi
authors.initials: M
authors.lastname: Fukagawa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002117:Calcitriol / Q000494:pharmacology*; D002118:Calcium / Q000097:blood; D002908:Chronic Disease; D005260:Female; D016166:Free Radical Scavengers / Q000378:metabolism; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D007674:Kidney Diseases / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D018167:Receptors, Calcitriol / Q000187:drug effects* / Q000378:metabolism; D006435:Renal Dialysis; D012709:Serum Albumin / Q000378:metabolism
chemical_list: D016166:Free Radical Scavengers; D010281:Parathyroid Hormone; D018167:Receptors, Calcitriol; D012709:Serum Albumin; D010758:Phosphorus; D002117:Calcitriol; D002118:Calcium